Cellebrite DI (CLBT) Stock Forecast & Price Target
Cellebrite DI · NASDAQ
$14.84+0.20 (+1.37%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Cellebrite DI, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $15.00 to $20.00, so the covering firms are broadly aligned. The average target of $17.50 sits 18% above the current $14.84. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.16 next quarter toward $0.66 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Cellebrite DI.
As of Jul, 5 of 5 firms rate CLBT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CLBT EPS & revenue forecast
EPS · NEXT QUARTER
$0.16
Range $0.15 – $0.17 · 8 analysts · +13% YoY
Next period, 8 analysts expect Cellebrite DI to earn $0.16 a share (range $0.15 – $0.17), versus $0.14 a year earlier. Full-year consensus is $0.55, growing to $0.66 the year after.
REVENUE · NEXT QUARTER
$150.3M
Range $147.4M – $153.0M · 8 analysts · +19% YoY
Revenue is expected to reach $150.3M (range $147.4M – $153.0M), +19.3% year-over-year. Full-year consensus is $568.0M, rising to $667.3M next year.
Top analysts covering Cellebrite DI
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLBT.
#1
Frank Takkinen
Lake Street · Rank #327
Buy
$21.00+41.5% to target
Overall win rate
26%
+ Follow
#2
Mike Cikos
Needham
Buy
$15.00+1.1% to target
Coverage
—
+ Follow
#3
Rudy Kessinger
DA Davidson
Buy
$20.00+34.8% to target
Coverage
—
+ Follow
#4
JV
Jeff Van Rhee
Craig-Hallum
Buy
No targeton CLBT
Coverage
—
+ Follow
#5
SE
Shaul Eyal
TD Cowen
Buy
$23.00+55.0% to target
Coverage
—
+ Follow
CLBT stock forecast FAQ
What is CLBT's average 12-month price target?+
The 2 analysts with a live target average $17.50 for Cellebrite DI over the next 12 months, ranging from a $20.00 high to a $15.00 low.
Is CLBT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CLBT?+
The Street-high target is $20.00 (DA Davidson), and the Street-low is $15.00 (Needham). The average of all 2 active targets is $17.50.
How many Wall Street analysts cover CLBT?+
5 analysts have an active rating on Cellebrite DI, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CLBT?+
Among analysts who currently cover CLBT, Frank Takkinen of Lake Street has the strongest overall Quantellect track record (Rank #327). Their current call is Buy with a $21.00 target.
What is Cellebrite DI's projected EPS for next quarter?+
The consensus estimate is $0.16 per share (range $0.15 – $0.17) across 8 analysts. Full-year EPS is projected at $0.55, rising to $0.66 the following year.
How much revenue is Cellebrite DI expected to report next quarter?+
Consensus revenue is $150.3M (range $147.4M – $153.0M). Full-year revenue is projected at $568.0M, growing to $667.3M next year.
Have analysts been upgrading or downgrading CLBT lately?+
As of Jul, 5 of 5 firms rate CLBT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLBT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
